← Back to Search

Telemedicine for Psoriatic Arthritis (PsOWell Trial)

N/A
Recruiting
Led By Alexis Ogdie-Beatty, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score >4 or a patient global assessment of greater than 4
Age 18-89
Must not have
PsAID score ≤4
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if telemedicine visits can help people with PsA improve their quality of life and reduce disease activity.

Who is the study for?
This trial is for adults aged 18-89 with active psoriatic arthritis symptoms, stable on current therapy, and not planning to change treatment soon. Participants must be willing to follow study procedures, have a mobile device for telemedicine visits, and score over 4 on the PsAID questionnaire or patient global assessment.
What is being tested?
The study tests how well patients with psoriatic arthritis respond to structured telemedicine visits aimed at encouraging lifestyle changes. It will evaluate if these remote consultations can improve life quality and disease management effectively.
What are the potential side effects?
Since this trial involves telemedicine rather than medication or invasive procedures, there are no direct side effects associated with typical drug interventions. However, participants may experience discomfort from lifestyle changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My Psoriatic Arthritis symptoms significantly impact my daily life.
Select...
I am between 18 and 89 years old.
Select...
I have Psoriatic Arthritis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My PsA symptoms are mild.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability
Effectiveness
Minimal Disease Activity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Interventional Telemedicine ArmExperimental Treatment1 Intervention
Single Arm Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Telemedicine
2008
Completed Phase 4
~3540

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,079 Previous Clinical Trials
42,721,534 Total Patients Enrolled
9 Trials studying Psoriatic Arthritis
3,192 Patients Enrolled for Psoriatic Arthritis
Alexis Ogdie-Beatty, MDPrincipal InvestigatorUniversity of Pennsylvania
3 Previous Clinical Trials
440 Total Patients Enrolled
2 Trials studying Psoriatic Arthritis
400 Patients Enrolled for Psoriatic Arthritis

Media Library

Telemedicine Clinical Trial Eligibility Overview. Trial Name: NCT05631223 — N/A
Psoriatic Arthritis Research Study Groups: Interventional Telemedicine Arm
Psoriatic Arthritis Clinical Trial 2023: Telemedicine Highlights & Side Effects. Trial Name: NCT05631223 — N/A
Telemedicine 2023 Treatment Timeline for Medical Study. Trial Name: NCT05631223 — N/A
~8 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top